🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We are excited to announce the first patient has been dosed in our phase 3 trial LiGeR-HN1 evaluating the efficacy and safety of petosemtamab plus pembrolizumab compared to pembrolizumab in 1L PD-L1+ r/m  #HNSCC #CloseInOnCancer ir.merus.nl/news-releases/…

We are excited to announce the first patient has been dosed in our phase 3 trial LiGeR-HN1 evaluating the efficacy and safety of petosemtamab plus pembrolizumab compared to pembrolizumab 1L r/m #HNSCC #CloseInOnCancer

Over the summer, we profiled some of our team members. You can find their stories, along with our current vacancies on our careers page: careers.merus.nl #CloseInOnCancer #JoinTheMerusMission

What is the optimal way to detect pathogenic gene fusions like NRG1?  Benjamin Weinberg, MD, highlights the advantages of RNA-based next generation sequencing and how it can capture what other tests might miss. Watch the video at bit.ly/4bHTrKJ #PrecisionOncology

We are excited for Adair to join the Merus team as our Internal Communications Officer. Welcome aboard! #CloseInOnCancer

Wishing everyone a safe and happy Halloween! #CloseInOnCancer

Please join us in welcoming Audrey as our Chief People Officer. Audrey has more than 25 years of experience attracting, developing, and retaining top talent in the pharmaceutical and biotechnology industries. We're excited to have her on the team as we #CloseInOnCancer.

The Merus team recently celebrated the end of summer and welcomed the start of the fall season with a fun and highly competitive outing. #Team #CloseInOnCancer

November is #PancreaticCancerAwareness Month, a time to support those battling one of the most challenging cancers to detect and treat. #CloseInOnCancer

Bill Lundberg, MD, Merus’ CEO, will participate in a fireside chat at the Guggenheim Securities Healthcare Innovation Conference. The live webcast will be available on our Investors page and for a limited time thereafter. #CloseInOnCancer

November is #LungCancerAwareness Month—a time to honor and support those impacted by the leading cause of cancer death worldwide. #CloseInOnCancer

Bill Lundberg, MD, Merus’ CEO, will participate in a fireside chat today at the Stifel 2024 Healthcare Conference. The live webcast will be available on our Investors page and for a limited time thereafter. #CloseInOnCancer

Attending AMP2024? Visit us at Booth 706. Did you know that NRG1+ tumors may have a higher rate of metastasis compared with KRAS+ tumors? Go to FindTheFusions.com and find out more about the metastatic potential of NRG1+ tumors. #AMP2024 #PrecisionOncology #FindTheFusions

We hope to see you at #ESMOAsia24 where clinical trial data on petosemtamab as 2L+ treatment of recurrent/metastatic #HNSCC will be presented. #ClosingInOnCancer ir.merus.nl/news-releases/…

Bill Lundberg, MD, Merus’ CEO, will present today at Citi’s 2025 Virtual Oncology Leadership Summit. The presentation will be available on our Investors page and for a limited time thereafter. #CloseInOnCancer

At Merus, every day, we bring a sense of urgency and a passion to help patients. In April we recognize the patients with recurrent/metastatic #HNSCC. We remain steadfast in our commitment to advance our lead cancer drug candidate petosemtamab as a potential new treatment for

Petosemtamab, a novel bispecific antibody targeting EGFR and LGR5, is being evaluated in two phase three registrational trials for recurrent/metastatic #HNSCC. The global LiGeR-HN1 trial has over 105 sites open across North and South America, Europe, Asia, and Australia. For more

Petosemtamab, a novel bispecific antibody targeting EGFR and LGR5, is being evaluated in two phase three registrational trials for recurrent/metastatic #HNSCC. The global LiGeR-HN2 trial has over 93 sites open across North and South America, Europe, Asia, and Australia. For more

In May 2024 and February 2025, the U.S. FDA granted Breakthrough Therapy designations to petosemtamab: as monotherapy in 2L+ r/m #HNSCC, and in combination with pembrolizumab in 1L PD-L1+ r/m #HNSCC, respectively. We are dedicated to advancing petosemtamab as a potential new

We look forward to sharing robust updated interim phase 2 data on petosemtamab plus pembrolizumab as first line treatment for PD-L1+ r/m #HNSCC, on the entire 45 patient data set, on an upcoming investor conference call on May 22 at 5:30 p.m. ET and in our presentation at